Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS.
Transfer of interferon β-1a into human breastmilk.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis.
17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice.
MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model.
Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
The relevance of animal models in multiple sclerosis research.
Seeing illness in art and medicine: a patient and printmaker collaboration.
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis.
Pregnancy and multiple sclerosis.
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice.
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®.
Parenteral Dilantin®
Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration.
Testosterone treatment in multiple sclerosis: a pilot study.
215ON201 BIIB033 In Acute Optic Neuritis (AON) (RENEW)
Characterisation of microglia during de- and remyelination: can they create a repair promoting environment?
FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)
Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination.
Pages
« first
‹ previous
…
15
16
17
18
19
20
21
22
23
…
next ›
last »